Clinical Testing News and Research

RSS

Diffregen awarded SBIR Phase 1 grant to advance Angiocidin towards human clinical trials

Diffregen LLC, a Temple University startup company, has been awarded a small business innovation research Phase 1 grant by the National Cancer Institute to advance Angiocidin, a university-created therapeutic to treat acute myeloid leukemia, to the doorstep of human clinical trials.

24 Oct 2013

New imaging tool could someday be used for routine breast cancer screenings

Breast cancer is one of the most common forms of cancer and cancer deaths among women worldwide. Routine screening can increase breast cancer survival by detecting the disease early and allowing doctors to address it at this critical stage.

23 Oct 2013

Illumina announces launch of TruGenome Undiagnosed Disease Test

Illumina, Inc. today announced the launch of its TruGenome Undiagnosed Disease Test provided by the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.

From Illumina, Inc. 22 Oct 2013

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced positive results from the Phase 1 portion of its Phase 1/1b study of defactinib (VS-6063) in combination with paclitaxel in patients with ovarian cancer that were presented at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

21 Oct 2013

Research Institute receives Fast Track status for its gene therapy product for treatment of SMA

AveXis and BioLife, synthetic biology platform companies, today announced that The Research Institute at Nationwide Children's Hospital received Fast Track designation from the U.S. Food and Drug Administration for its scAAV9.CB.SMN gene therapy product for the treatment of spinal muscular atrophy (SMA).

19 Oct 2013

ESTEVE reports positive top line results from E-58425 phase II trial for acute pain

ESTEVE, a pharmaceutical company focused on developing novel therapeutics for pain today announces positive top line results from its recently completed phase II trial, which was designed to evaluate the efficacy and safety of E-58425 in acute pain.

16 Oct 2013

New method for improving cord blood transplant success

Starting with a discovery in zebrafish in 2007, Harvard Stem Cell Institute researchers have published initial results of a Phase Ib human clinical trial of a therapeutic that has the potential to improve the success of blood stem cell transplantation.

9 Oct 2013

CARUNDA24: A non-invasive continuous blood pressure measurement system

Freienbach, Switzerland: About 1 in 4 people in Switzerland suffer from high blood pressure; worldwide more than 1 billion people are affected increasing the risk of heart attack, cerebral haemorrhage or a stroke. Unfortunately, most affected people don't measure their blood pressure regularly as the measurement method is too complicated and uncomfortable to be part of a daily routine.

8 Oct 2013

Scientists at Oklahoma Medical Research Foundation identify six new Sj-gren-related genes

With the completion of the first genome-wide association study for Sj-gren's syndrome, an international coalition of researchers led by scientists at the Oklahoma Medical Research Foundation has identified six new disease-related genes.

7 Oct 2013

Autism Speaks launches the Preclinical Autism Consortium for Therapeutics

Autism Speaks, the world's leading autism science and advocacy organization, today announced the launch of the Preclinical Autism Consortium for Therapeutics (PACT).

4 Oct 2013

Final patient completion of phase II study of TR040303 in patients treated for acute myocardial infarction announced by Trophos

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announces today the final patient completion of a phase II study of TR040303 in patients treated for acute myocardial infarction (MI). Outcome data of this study is expected to be available towards the end of 2013.

2 Oct 2013

HOOKVAC consortium awarded grant to develop, test vaccine for human hookworm

The HOOKVAC consortium, led by the Academic Medical Center at the University of Amsterdam, today announced it has been awarded a grant of six million Euros from the European Commission FP7 programme to expand the Sabin Vaccine Institute Product Development Partnership’s (Sabin PDP) work to develop and test a vaccine for human hookworm, a disease that infects 600-700 million of the world’s poorest people.

27 Sep 2013

HOOKVAC consortium to begin first clinical testing of human hookworm vaccine in West Africa

The HOOKVAC consortium, led by the Academic Medical Center (AMC) at the University of Amsterdam, today announced it has been awarded a grant of six million Euros from the European Commission FP7 programme to expand the Sabin Vaccine Institute Product Development Partnership's (Sabin PDP) work to develop and test a vaccine for human hookworm, a disease that infects 600-700 million of the world's poorest people.

27 Sep 2013

Study evaluates outcomes of youth athletes after sports-related concussion

Recent scientific findings have raised the fear that young athletes may fare worse after sustaining a sports-related concussion than older athletes. Researchers from Vanderbilt University School of Medicine compared symptoms associated with concussion in middle/high school-age athletes with those in college-age athletes to determine whether age-related differences exist.

25 Sep 2013

Applied Integrin Sciences' drug candidate eliminates ovarian cancer tumors in pre-clinical study

Applied Integrin Sciences, Inc. announced today that its first cancer therapeutic drug candidate eliminated all intraperitoneal ovarian cancer tumors in a pre-clinical study testing a novel treatment regimen.

21 Sep 2013

UW researchers receive $390,000 from 5 organizations dedicated to fostering technology

A product development team at the University of Washington (UW) will receive $390,000 from five organizations dedicated to fostering technology commercialization in Washington.

7 Sep 2013

New compound offers way to treat migraine and other disorders of central nervous system

For many migraine sufferers, bright lights are a surefire way to exacerbate their headaches. And for some night-shift workers, just a stroll through a brightly lit parking lot during the morning commute home can be enough to throw off their body's daily rhythms and make daytime sleep nearly impossible. But a new molecule that selectively blocks specialized light-sensitive receptors in the eyes could help both these groups of people, without affecting normal vision.

28 Aug 2013

TRS receives FDA approval for Cranial Bone Void Filler product

Tissue Regeneration Systems, Inc. today announced that it has received 510K approval from the U.S. Food and Drug Administration for its Cranial Bone Void Filler product, indicated for use in the repair of neurosurgical burr holes.

26 Aug 2013

Tigercat and Velocity Pharmaceutical announce submission of IND application to FDA for VPD-737

Velocity Pharmaceutical Development, LLC ("VPD") and Tigercat Pharma, Inc., ("Tigercat") announced today the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for VPD-737 for the treatment of chronic pruritus.

19 Aug 2013

Discovery Transformation Program funds four projects for diabetes research

The Minnesota Partnership for Biotechnology and Medical Genomics announced four research projects selected for funding from the 2013 Discovery Transformation Grant Program.

13 Aug 2013